Bath & Body Works (NYSE:BBWI) Director Acquires $50,111.57 in Stock

Bath & Body Works, Inc. (NYSE:BBWI) Director Francis Hondal bought 3,343 shares of Bath & Body Works stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average cost of $14.99 per share, for a total transaction of $50,111.57. Following the acquisition, the director owned 21,554 shares of the company’s stock, valued at $323,094.46. This represents a 18.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Bath & Body Works Stock Up 4.9%

Bath & Body Works stock traded up $0.73 during trading on Monday, reaching $15.58. The stock had a trading volume of 18,349,612 shares, compared to its average volume of 5,908,003. Bath & Body Works, Inc. has a 52-week low of $14.27 and a 52-week high of $41.87. The stock has a market cap of $3.21 billion, a PE ratio of 4.62, a P/E/G ratio of 0.86 and a beta of 1.53. The business has a 50 day moving average price of $24.58 and a 200 day moving average price of $28.11.

Bath & Body Works (NYSE:BBWI) last announced its quarterly earnings data on Thursday, November 20th. The company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.05). The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.49 earnings per share. Bath & Body Works has set its FY 2025 guidance at 2.870- EPS. Q4 2025 guidance at 1.700- EPS. On average, equities analysts predict that Bath & Body Works, Inc. will post 3.3 EPS for the current fiscal year.

Bath & Body Works Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Friday, November 21st will be paid a $0.20 dividend. The ex-dividend date is Friday, November 21st. This represents a $0.80 dividend on an annualized basis and a yield of 5.1%. Bath & Body Works’s dividend payout ratio (DPR) is currently 24.62%.

Institutional Investors Weigh In On Bath & Body Works

Several hedge funds have recently made changes to their positions in BBWI. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Bath & Body Works during the second quarter worth about $33,000. First Horizon Corp acquired a new stake in Bath & Body Works during the 3rd quarter worth approximately $29,000. SVB Wealth LLC purchased a new position in shares of Bath & Body Works in the 1st quarter valued at approximately $35,000. Geneos Wealth Management Inc. grew its stake in shares of Bath & Body Works by 217.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after purchasing an additional 801 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in shares of Bath & Body Works by 63.3% in the second quarter. Parallel Advisors LLC now owns 1,241 shares of the company’s stock valued at $37,000 after purchasing an additional 481 shares during the period. Institutional investors and hedge funds own 95.14% of the company’s stock.

Analyst Ratings Changes

BBWI has been the subject of several analyst reports. New Street Research set a $26.00 price objective on Bath & Body Works in a research report on Monday. JPMorgan Chase & Co. decreased their target price on Bath & Body Works from $26.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday. Wall Street Zen downgraded Bath & Body Works from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Robert W. Baird reiterated a “neutral” rating and issued a $19.00 price target (down from $33.00) on shares of Bath & Body Works in a research note on Thursday. Finally, UBS Group reduced their price objective on shares of Bath & Body Works from $32.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday. Seven analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $26.84.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.